Literature DB >> 26650888

Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.

Stephen J Salipante1, Andrew Adey2, Anju Thomas1, Choli Lee2, Yajuan J Liu3, Akash Kumar2, Alexandra P Lewis2, David Wu1, Jonathan R Fromm1, Jay Shendure2.   

Abstract

Investigation of the genetic lesions underlying classical Hodgkin lymphoma (CHL) has been challenging due to the rarity of Hodgkin and Reed-Sternberg (HRS) cells, the pathognomonic neoplastic cells of CHL. In an effort to catalog more comprehensively recurrent copy number alterations occurring during oncogenesis, we investigated somatic alterations involved in CHL using whole-genome sequencing-mediated copy number analysis of purified HRS cells. We performed low-coverage sequencing of small numbers of intact HRS cells and paired non-neoplastic B lymphocytes isolated by flow cytometric cell sorting from 19 primary cases, as well as two commonly used HRS-derived cell lines (KM-H2 and L1236). We found that HRS cells contain strikingly fewer copy number abnormalities than CHL cell lines. A subset of cases displayed nonintegral chromosomal copy number states, suggesting internal heterogeneity within the HRS cell population. Recurrent somatic copy number alterations involving known factors in CHL pathogenesis were identified (REL, the PD-1 pathway, and TNFAIP3). In eight cases (42%) we observed recurrent copy number loss of chr1:2,352,236-4,574,271, a region containing the candidate tumor suppressor TNFRSF14. Using flow cytometry, we demonstrated reduced TNFRSF14 expression in HRS cells from 5 of 22 additional cases (23%) and in two of three CHL cell lines. These studies suggest that TNFRSF14 dysregulation may contribute to the pathobiology of CHL in a subset of cases.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26650888      PMCID: PMC4713316          DOI: 10.1002/gcc.22331

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  50 in total

1.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

2.  Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease.

Authors:  H Kamesaki; S Fukuhara; E Tatsumi; H Uchino; H Yamabe; H Miwa; S Shirakawa; M Hatanaka; T Honjo
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

Review 3.  Aberrant rel/nfkb genes and activity in human cancer.

Authors:  B Rayet; C Gélinas
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

4.  Classical Hodgkin lymphoma is associated with frequent gains of 17q.

Authors:  Daniel T Y Chui; David Hammond; Margaret Baird; Lesley Shield; Robert Jackson; Ruth F Jarrett
Journal:  Genes Chromosomes Cancer       Date:  2003-10       Impact factor: 5.006

5.  Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.

Authors:  Annette Lake; Lesley A Shield; Pablo Cordano; Daniel T Y Chui; Julie Osborne; Shauna Crae; Katherine S Wilson; Sabrina Tosi; Samantha J L Knight; Stefan Gesk; Reiner Siebert; Ron T Hay; Ruth F Jarrett
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

6.  Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.

Authors:  Jay Gunawardana; Fong Chun Chan; Adèle Telenius; Bruce Woolcock; Robert Kridel; King L Tan; Susana Ben-Neriah; Anja Mottok; Raymond S Lim; Merrill Boyle; Sanja Rogic; Lisa M Rimsza; Chrystelle Guiter; Karen Leroy; Philippe Gaulard; Corinne Haioun; Marco A Marra; Kerry J Savage; Joseph M Connors; Sohrab P Shah; Randy D Gascoyne; Christian Steidl
Journal:  Nat Genet       Date:  2014-02-16       Impact factor: 38.330

7.  Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.

Authors:  Christian Steidl; Arjan Diepstra; Tang Lee; Fong Chun Chan; Pedro Farinha; King Tan; Adele Telenius; Lorena Barclay; Sohrab P Shah; Joseph M Connors; Anke van den Berg; Randy D Gascoyne
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

8.  Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Claudia Döring; Verena Brune; Carel J M van Noesel; Wolfram Klapper; Gunhild Mechtersheimer; Brunangelo Falini; Ralf Küppers; Martin-Leo Hansmann
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

9.  A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3).

Authors:  Victor Enciso-Mora; Peter Broderick; Yussanne Ma; Ruth F Jarrett; Henrik Hjalgrim; Kari Hemminki; Anke van den Berg; Bianca Olver; Amy Lloyd; Sara E Dobbins; Tracy Lightfoot; Flora E van Leeuwen; Asta Försti; Arjan Diepstra; Annegien Broeks; Jayaram Vijayakrishnan; Lesley Shield; Annette Lake; Dorothy Montgomery; Eve Roman; Andreas Engert; Elke Pogge von Strandmann; Katrin S Reiners; Ilja M Nolte; Karin E Smedby; Hans-Olov Adami; Nicola S Russell; Bengt Glimelius; Stephen Hamilton-Dutoit; Marieke de Bruin; Lars P Ryder; Daniel Molin; Karina Meden Sorensen; Ellen T Chang; Malcolm Taylor; Rosie Cooke; Robert Hofstra; Helga Westers; Tom van Wezel; Ronald van Eijk; Alan Ashworth; Klaus Rostgaard; Mads Melbye; Anthony J Swerdlow; Richard S Houlston
Journal:  Nat Genet       Date:  2010-10-31       Impact factor: 38.330

10.  Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma.

Authors:  Junko Nomoto; Nobuhiro Hiramoto; Motohiro Kato; Masashi Sanada; Akiko Miyagi Maeshima; Hirokazu Taniguchi; Fumie Hosoda; Yoshitaka Asakura; Wataru Munakata; Naohiro Sekiguchi; Dai Maruyama; Takashi Watanabe; Hitoshi Nakagama; Kengo Takeuchi; Kensei Tobinai; Seishi Ogawa; Yukio Kobayashi
Journal:  BMC Cancer       Date:  2012-10-05       Impact factor: 4.430

View more
  4 in total

1.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.

Authors:  Vincent Camus; Aspasia Stamatoullas; Sylvain Mareschal; Pierre-Julien Viailly; Nasrin Sarafan-Vasseur; Elodie Bohers; Sydney Dubois; Jean Michel Picquenot; Philippe Ruminy; Catherine Maingonnat; Philippe Bertrand; Marie Cornic; Valérie Tallon-Simon; Stéphanie Becker; Liana Veresezan; Thierry Frebourg; Pierre Vera; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2016-06-13       Impact factor: 9.941

2.  An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.

Authors:  A Lollies; S Hartmann; M Schneider; T Bracht; A L Weiß; J Arnolds; L Klein-Hitpass; B Sitek; M-L Hansmann; R Küppers; M A Weniger
Journal:  Leukemia       Date:  2017-06-29       Impact factor: 11.528

3.  Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.

Authors:  Kirsty Wienand; Bjoern Chapuy; Chip Stewart; Andrew J Dunford; David Wu; Jaegil Kim; Atanas Kamburov; Timothy R Wood; Fathima Zumla Cader; Matthew D Ducar; Aaron R Thorner; Anwesha Nag; Alexander T Heubeck; Michael J Buonopane; Robert A Redd; Kamil Bojarczuk; Lee N Lawton; Philippe Armand; Scott J Rodig; Jonathan R Fromm; Gad Getz; Margaret A Shipp
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  Molecular biology of Hodgkin lymphoma.

Authors:  Marc A Weniger; Ralf Küppers
Journal:  Leukemia       Date:  2021-03-08       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.